• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Cleveland Clinic spinout Infuseon wins FDA nod for CNS drug delivery device

June 13, 2017 By Sarah Faulkner

Infuseon Therapeutics
Credit: Infuseon Therapeutics

Cleveland Clinic spinout Infuseon Therapeutics said today that its novel central nervous system delivery device won 510(k) clearance from the FDA as a therapeutic delivery device.

The company’s Cleveland Multiport Catheter, which won FDA clearance in March, was designed to effectively deliver therapeutics to the brain. Usually, the blood brain barrier prevents drugs delivered in traditional methods from reaching their target.

The device is composed of 4 independent delivery microcatheters and was initially approved to deliver chemotherapy to the ventricles of the brain. Infuseon said the CMC is being evaluated in IND-based pilot clinical trials as a loco-regional delivery device with an MRI-visible tracer in patients with recurrent high grade gliomas.

“This clearance of the CMC is important to developers of drugs and biologics that are intended for direct delivery to the CNS, as they are looking to use an FDA-cleared catheter for their IND-based clinical trials,” Dr. Michael Vogelbaum said in prepared remarks.

Vogelbaum is a professor of neurosurgery at the Cleveland Clinic Lerner College of Medicine and associate director of Cleveland Clinic’s Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center. He also designed the device.

The 1st patient was treated with the CMC in December 2014 and since then, 12 patients with malignant glioma have finished treatment with the device. In these procedures, 2 CMC devices were placed in each patient using traditional neurosurgical stereotactic methods. Researchers infused a chemotherapy and an MRI-visible tracer into the tumor or tumor-infiltrated brain tissue using the microcatheters for up to 96 hours.

Using intermittent MRI monitoring, the company has seen that the infusate widely distributed into the tumor-infiltrated brain thanks to the delivery device.

“The extent of brain tissue covered and the reliability of the technique in these patients to date have surpassed past experience with other CED devices,” Vogelbaum said.

The company reported that it will continue to conduct additional studies to set optimal parameters for use of the CMC in solid tumors and in tumor-infiltrated brain. Infuseon also said it plans to identify other conditions affecting the brain, CNS and solid organs that could benefit from treatment with the device.

The company is on the look-out for strategic partners with proprietary agents that could be delivered through the CMC, Infuseon added.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Neurological, Pharmaceuticals, Regulatory/Compliance Tagged With: Cleveland Clinic, infuseontherapeutics

IN CASE YOU MISSED IT

  • BD stock up on Street-beating preliminary quarterly revenue numbers
  • Locate Bio lands FDA breakthrough nod for bone infection device
  • PerkinElmer to acquire Oxford Immunotec
  • Evonik buys polymers business from Durect Corp.
  • New Croatian notified body designated to European MDR

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS